Predictive Value of Tumor Microenvironment PET/CT for Response and Prognosis in Aggressive Lymphoma: A Multicenter Study
Recruiting now · Not applicable
Conditions studied: Aggressive Lymphoma
In brief
This multicenter study aims to evaluate the predictive value of tumor microenvironment PET/CT imaging for treatment response and prognosis in patients with aggressive lymphoma. Eligible patients with histologically confirmed aggressive lymphoma will undergo FAPI PET/CT imaging, and selected patients who are candidates for immunotherapy will undergo Grazytracer PET/CT imaging. These imaging methods are intended to assess fibroblast activation protein expression and granzyme B activity in lymphoma lesions, reflecting cancer-associated fibroblasts and cytotoxic T-cell activity in the tumor microenvironment. The study will explore optimal imaging assessment criteria and develop clinical-pathological-imaging models to predict treatment response, prognosis, and the relationship between tumor heterogeneity and refractory or relapsed disease.
Key facts
- Study ID
- NCT07657494
- Run by
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- People needed
- 94
- Starts
- 2024-07-11
- Expected to finish
- 2026-12-31
- Last updated by the study team
- 2026-06-18
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Histologically confirmed aggressive lymphoma.
- Baseline PET/CT showing moderate to high FDG uptake in lymphoma lesions.
- No previous history of malignant tumors.
- No significant cardiac, hepatic, or renal dysfunction.
- Expected survival of at least 6 months and ability to complete follow-up.
You may not qualify if…
- Low FDG uptake on baseline PET/CT.
- Lymphoma lesions have been surgically removed, with no positive lesions available for evaluation.
- Active or uncontrolled chronic inflammation or infection.
- Uncontrolled diabetes mellitus.
- Incomplete clinical data or loss to follow-up.
- Refusal to sign the informed consent form.
- Inability to lie supine for 30 minutes.
Where it is running
- National Cancer Center/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College — Beijing, Chao Yang, China (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.